Zentalis Pharmaceuticals Llc (ZNTL) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Zentalis Pharmaceuticals Llc stock $1.84, price $1.72, upside +7.0%, quality 47 out of 100. Rating: fairly valued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range $1.04 – $84.79 · fair‑value band $1.21 – $2.30 · the $1.72 price screens below the $1.84 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Zentalis Pharmaceuticals Llc in your weekly email
Every Wednesday you see whether Zentalis Pharmaceuticals Llc is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.
Show moreShow less
It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer.
It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Stock analysis
Zentalis Pharmaceuticals Llc (ZNTL) currently trades at $1.72, while our model-based Fair Value estimate is $1.84, so the stock looks roughly fairly valued today (gap 6.5%).
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $1.21 (bear) to $2.30 (bull), the price of $1.72 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Zentalis Pharmaceuticals Llc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$137M in FY2025.
Key figures
Market cap $162M Micro · P/S ratio 7.23 · EPS (TTM) $−1.96 · Return on equity −66.8% · Return on assets (EBIT) −47.5% (5-year average) · Revenue (TTM) $26.9M · Free cash flow −$125M · Net debt $3.6M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).
What moves the price
The share trades about 74% below its 52-week high and 34% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 7%, ZNTL screens richer than that median.
Fair Value models
Bear$1.21Fair Value $1.84Bull$2.30
Price $1.72 · Upside +7.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, no officer or director bought or sold shares on the open market.
BuyWilliam Thurman Walters10% owner2× since Dec 31, 2025: 10,794,973 shares, avg. $2.12$22.9MAug 14, 2026
SaleVincent VultaggioPAO and PFO2× since Feb 2, 2026: 43,320 shares, avg. $2.43$105,418Feb 10, 202610b5-1 plan
SaleJulia Marie EastlandCEO & President, Director8,755 shares at $2.43$21,239Feb 9, 2026
SaleIngmar BrunsChief Medical Officer3,297 shares at $2.43$7,998Feb 9, 2026
SaleDavid E. Goel10% owner7,500,000 shares at $1.33$10.0MDec 15, 2025
Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Zentalis Pharmaceuticals Llc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 557 stocks
Beats the industry median on 6/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score47 · Above median
Fair Value upside+7.0% · Top 25%
Profitability
Return on assets−47.4% · Bottom 25%
Operating margin (12 months)0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Zentalis Pharmaceuticals Llc (ZNTL) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $1.84 versus a price of $1.72, about +7% upside (fairly valued).
What is the fair value of ZNTL?
Our model-based fair value for Zentalis Pharmaceuticals Llc is $1.84 (as of Nov 8, 2026), built from audited fundamentals. The current price: $1.72.
What is the quality score of ZNTL?
Zentalis Pharmaceuticals Llc has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zentalis Pharmaceuticals Llc (ZNTL)?
Our model-based price target is the fair value of $1.84 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $1.21, optimistic scenario $2.30. It is a calculation from audited fundamentals, not an analyst target.
What is the Zentalis Pharmaceuticals Llc stock forecast for 2026?
Our models put fair value at $1.84, about +7% upside versus a price of $1.72 (fairly valued). Cautious scenario $1.21, optimistic scenario $2.30. The calculation is refreshed regularly with new filings.
What is the revenue of Zentalis Pharmaceuticals Llc (ZNTL)?
Zentalis Pharmaceuticals Llc reported trailing-twelve-month revenue of about $26.9M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Zentalis Pharmaceuticals Llc (ZNTL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zentalis Pharmaceuticals Llc it is $1.84 per share (as of Nov 8, 2026), against a price of $1.72. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Zentalis Pharmaceuticals Llc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, ZNTL trades below its calculated fair value: price $1.72, fair value $1.84, a gap of about +7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ZNTL?
No. The price is what the market pays today ($1.72); the fair value is what the company's own numbers justify ($1.84). For Zentalis Pharmaceuticals Llc the two are $0.1200 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zentalis Pharmaceuticals Llc worth?
The market values Zentalis Pharmaceuticals Llc at about $162M (market capitalisation, as of Nov 8, 2026). Per share that is $1.72; our models calculate a fair value of $1.84 per share.
What do the bullish and bearish scenarios say about ZNTL?
Our models span a range for Zentalis Pharmaceuticals Llc: cautious scenario $1.21, base $1.84, optimistic $2.30 per share (as of Nov 8, 2026, price $1.72). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Zentalis Pharmaceuticals Llc (ZNTL)?
Balance-sheet figures for Zentalis Pharmaceuticals Llc (as of Nov 8, 2026): return on equity −66.8%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is ZNTL from its 52-week high?
Zentalis Pharmaceuticals Llc trades at $1.72, about 74% below its 52-week high of $6.61 and 34% above the low of $1.28 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $1.84 is for.
Which stocks are comparable to Zentalis Pharmaceuticals Llc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zentalis Pharmaceuticals Llc stock attractive at the current price?
The data as of Nov 8, 2026: price $1.72, calculated fair value $1.84 (+7%), Quality Score 47/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ZNTL calculated?
We run Zentalis Pharmaceuticals Llc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $1.84 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Zentalis Pharmaceuticals Llc currently trades 7% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zentalis Pharmaceuticals Llc (ZNTL)?
The closing price on Nov 6, 2026 was $1.72. Our model-based fair value is $1.84, about +7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zentalis Pharmaceuticals Llc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($1.21 to $2.30) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Zentalis Pharmaceuticals Llc
How large is the market capitalisation of Zentalis Pharmaceuticals Llc (ZNTL)?
The market capitalisation of Zentalis Pharmaceuticals Llc is $162M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zentalis Pharmaceuticals Llc (ZNTL)?
The price-to-sales ratio of Zentalis Pharmaceuticals Llc is 7.23 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zentalis Pharmaceuticals Llc (ZNTL)?
Earnings per share at Zentalis Pharmaceuticals Llc are $−1.96. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Zentalis Pharmaceuticals Llc (ZNTL)?
The return on equity (ROE) of Zentalis Pharmaceuticals Llc is −66.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zentalis Pharmaceuticals Llc (ZNTL)?
On an EBIT basis the return on assets of Zentalis Pharmaceuticals Llc is −47.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Zentalis Pharmaceuticals Llc (ZNTL) generate?
The free cash flow of Zentalis Pharmaceuticals Llc is −$125M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Zentalis Pharmaceuticals Llc (ZNTL) carry?
The net debt of Zentalis Pharmaceuticals Llc is $3.6M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Zentalis Pharmaceuticals Llc in the live analysis
One click puts Zentalis Pharmaceuticals Llc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026
